Novartis Ag Stock Today

NVSEF Stock  USD 95.68  0.71  0.74%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Less than 9

 
100  
 
Zero
Low
Novartis is trading at 95.68 as of the 28th of March 2024. This is a -0.74 percent down since the beginning of the trading day. The stock's lowest day price was 95.68. Novartis has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Novartis AG are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of April 2022 and ending today, the 28th of March 2024. Click here to learn more.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. The company has 2.12 B outstanding shares. More on Novartis AG

Moving against Novartis Pink Sheet

  0.54C Citigroup Aggressive PushPairCorr
  0.53PIFMF PT Indofood SuksesPairCorr
  0.45LLY Eli Lilly And Financial Report 25th of April 2024 PairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Novartis Pink Sheet Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Novartis' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Novartis or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
President CEOChris Ilsley
Business ConcentrationDrug Manufacturers—General, Healthcare (View all Sectors)
Novartis AG [NVSEF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Mega-Cap' category with a current market capitalization of 183.29 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novartis's market, we take the total number of its shares issued and multiply it by Novartis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novartis AG classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 2.12 B outstanding shares. Novartis AG has accumulated about 19.1 B in cash with 14.24 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.81.
Check Novartis Probability Of Bankruptcy
Ownership Allocation
Novartis AG maintains a total of 2.12 Billion outstanding shares. 30% of Novartis outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Novartis Ownership Details

Novartis Stock Price Odds Analysis

In reference to a normal probability distribution, the odds of Novartis jumping above the current price in 90 days from now is under 95%. The Novartis AG probability density function shows the probability of Novartis pink sheet to fall within a particular range of prices over 90 days. Assuming the 90 days horizon Novartis AG has a beta of -0.8451. This indicates as returns on benchmark increase, returns on holding Novartis are expected to decrease at a much lower rate. During the bear market, however, Novartis AG is likely to outperform the market. Additionally, novartis AG has an alpha of 0.0816, implying that it can generate a 0.0816 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 95.68HorizonTargetOdds Above 95.68
5.25%90 days
 95.68 
94.67%
Based on a normal probability distribution, the odds of Novartis to move above the current price in 90 days from now is under 95 (This Novartis AG probability density function shows the probability of Novartis Pink Sheet to fall within a particular range of prices over 90 days) .

Novartis AG Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Novartis market risk premium is the additional return an investor will receive from holding Novartis long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Novartis. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Novartis' alpha and beta are two of the key measurements used to evaluate Novartis' performance over the market, the standard measures of volatility play an important role as well.

Novartis Stock Against Markets

Picking the right benchmark for Novartis pink sheet is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Novartis pink sheet price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Novartis is critical whether you are bullish or bearish towards Novartis AG at a given time. Please also check how Novartis' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Novartis without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Money Flow Index Now

   

Money Flow Index

Determine momentum by analyzing Money Flow Index and other technical indicators
All  Next Launch Module

Novartis Corporate Directors

Novartis corporate directors refer to members of a Novartis board of directors. The board of directors generally takes responsibility for the Novartis' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Novartis' board members must vote for the resolution. The Novartis board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Ton BuechnerNon-Executive Independent DirectorProfile
Pierre LandoltMember of the Board of DirectorsProfile
Elizabeth DohertyNon-Executive Independent DirectorProfile
Srikant DatarMember of the Board of DirectorsProfile

How to buy Novartis Pink Sheet?

Before investing in Novartis, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Novartis. To buy Novartis stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Novartis. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Novartis stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Novartis AG stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Novartis AG stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Novartis AG, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments.

Already Invested in Novartis AG?

The danger of trading Novartis AG is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Novartis is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Novartis. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Novartis AG is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
Note that the Novartis AG information on this page should be used as a complementary analysis to other Novartis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Complementary Tools for Novartis Pink Sheet analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Stocks Directory
Find actively traded stocks across global markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.